Cohance Lifesciences Limited will host a conference call on August 5, 2026, to discuss its unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27). The company filed a notice with BSE Limited and National Stock Exchange of India Limited on July 23, 2026, confirming the schedule for investors and analysts to review the performance metrics. The results are set to be announced earlier on the same day as the call.

The session is scheduled for 6:30 PM IST and will commence with a brief management discussion regarding the financial outcomes. Following the presentation, senior management will engage in an interactive Question & Answer session to address queries from participants. The filing was signed by Sisir K. Mishra, Company Secretary & Compliance Officer.

Conference Call Details

The company has provided domestic and international dial-in numbers for participants. Attendees are advised to dial in 5 to 10 minutes prior to the scheduled start time to ensure timely connection. Pre-registration is available via the provided link to facilitate seamless access without waiting for an operator.

Upon registration, attendees will receive dial-in numbers, a passcode, and a PIN via the email address provided during registration. Participants must use these credentials to connect to the call on the scheduled date.

Investor Contacts

For further information regarding the conference call, investors may contact the following representatives:

Cyndrella Carvalho Head - Investor Relations Cohance Lifesciences Limited Tel: 040 2354 3311 Email: cyndrella.carvalho@cohance.com

Gavin Desa CDR India Tel: +91 98206 37649 Email: gavin@cdr-india.com

Jusmiral Holdings Limited, the promoter of Cohance Lifesciences Limited , has declared that it has not created any encumbrance on the company's shares during the financial year 2025-26. The disclosure, submitted to the stock exchanges, confirms that no direct or indirect charges were placed on the shares other than those previously disclosed. This assurance provides clarity to shareholders regarding the status of the promoter's holding amidst regulatory compliance requirements.

The declaration was made pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011. Jusmiral Holdings Limited, along with persons acting in concert—specifically Berhyanda Limited and Jusmiral Midco Limited—formally communicated this status to the Manager of the Department of Corporate Services at BSE Limited and the Manager of the Listing Department at National Stock Exchange of India Limited.

Regulatory Filing Details

The communication addressed to the exchanges explicitly stated that the promoter group has not made any fresh encumbrance on the shares of Cohance Lifesciences Limited. The filing serves as a formal update to the records of the exchanges and the Audit Committee of the company.

Key Entities Involved

The letter, dated April 7, 2026, was signed by Christodoulos Patsalides, Director of Jusmiral Holdings Limited. A copy of the declaration was also forwarded to the Audit Committee of Cohance Lifesciences Limited for their information and records.